Suppr超能文献

药物性瞳孔散大作为预测术中虹膜膨隆综合征风险的一项预测性试验。

Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.

机构信息

Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy.

出版信息

J Cataract Refract Surg. 2011 Aug;37(8):1447-54. doi: 10.1016/j.jcrs.2011.02.030.

Abstract

PURPOSE

To evaluate the effect of α1-adrenergic receptor antagonists (α1-ARAs) on pupil diameter and determine whether the diameter predicts intraoperative floppy-iris syndrome (IFIS).

SETTING

Ophthalmology Section, Palermo University, Palermo, Italy.

DESIGN

Prospective cohort study.

METHODS

Male outpatients taking tamsulosin, α(1)-ARAs, or no α(1)-ARAs having phacoemulsification were recruited. Pupils were measured 1 month preoperatively, immediately preoperatively, and postoperatively under mesopic low (0.4 lux) and high (4.0 lux) illumination after pharmacologic dilation. The IFIS severity was graded.

RESULTS

Each group comprised 50 patients. Pharmacologic dilation in both α(1)-ARA groups was statistically significantly less than in the no α1-ARA group 1 month preoperatively, immediately before surgery, and postoperatively (P=.001, P<.0005, and P<.0005, respectively). The IFIS incidence differed significantly between the tamsulosin and other α(1)-ARA groups and the no α1-ARA group (P<.0005 and P=.017, respectively) and between the tamsulosin group and the other α1-ARA group (P=.027). On regression analysis, the hazard ratio for overall IFIS incidence was 3.8 in the other α(1)-ARA group (P=.012) and 10.1 in the tamsulosin group (P<.0005). Pupil size was inversely related to IFIS incidence and severity (P<.0005). A dilated pupil of 7.0 mm or smaller had 73% sensitivity and 95% specificity for predicting IFIS (P=.0001).

CONCLUSIONS

Pupil dilation was inhibited by α(1)-ARAs, in particular tamsulosin. For a pupil 7.0 mm or smaller, the risk for IFIS existed regardless of α(1)-ARAs treatment, which surgeons should take into consideration.

摘要

目的

评估α1-肾上腺素能受体拮抗剂(α1-ARAs)对瞳孔直径的影响,并确定瞳孔直径是否可预测术中虹膜膨隆综合征(IFIS)。

设置

意大利巴勒莫大学眼科科。

设计

前瞻性队列研究。

方法

招募正在服用坦索罗辛、α1-ARAs 或未服用 α1-ARAs 的男性门诊患者,这些患者需接受超声乳化白内障吸除术。在药物散瞳后,于术前 1 个月、术前即刻和术后在中低光照(0.4 lux)和高照度(4.0 lux)下测量瞳孔。对 IFIS 严重程度进行分级。

结果

每个组包含 50 名患者。术前 1 个月、术前即刻和术后,α1-ARA 两组的药物散瞳均显著小于未用 α1-ARA 组(P=.001、P<.0005 和 P<.0005)。坦索罗辛组和其他 α1-ARA 组与未用 α1-ARA 组之间的 IFIS 发生率差异有统计学意义(P<.0005 和 P=.017),坦索罗辛组与其他 α1-ARA 组之间的 IFIS 发生率差异也有统计学意义(P=.027)。回归分析显示,其他 α1-ARA 组总体 IFIS 发生率的危险比为 3.8(P=.012),坦索罗辛组为 10.1(P<.0005)。瞳孔大小与 IFIS 发生率和严重程度呈负相关(P<.0005)。瞳孔直径为 7.0 毫米或更小预测 IFIS 的敏感性为 73%,特异性为 95%(P=.0001)。

结论

α1-ARAs,特别是坦索罗辛,可抑制瞳孔扩张。对于直径为 7.0 毫米或更小的瞳孔,无论是否使用 α1-ARAs 治疗,IFIS 的风险都存在,外科医生应予以考虑。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验